Great Danes: Two Nordic biotechs name their chief ex­ec­u­tives; Ax­el Hoos bids adieu to Glax­o­SmithK­line, be­comes CEO of small on­col­o­gy play­er

Don’t let the short week de­ceive you. Peer Re­view has a lot to get to:

→ When our Nicole De­Feud­is pro­filed new Co­di­ak CMO Jen­nifer Whel­er, she al­so wrote that Ben­ny Sorensen would be tak­ing on the role of SVP of strate­gic projects af­ter head­ing up clin­i­cal de­vel­op­ment. That didn’t last long.

We’ve learned that Sorensen has re­signed to lead Dan­ish biotech Hemab Ther­a­peu­tics as CEO. Backed by No­vo Hold­ings, Hemab is a three-year-old com­pa­ny that de­vel­ops bis­pe­cif­ic an­ti­bod­ies for rare bleed­ing dis­or­ders that had been helmed by co-founder Jo­han Faber. Sorensen, an Al­ny­lam vet, will still be con­nect­ed to Co­di­ak as a mem­ber of the sci­en­tif­ic ad­vi­so­ry board and a clin­i­cal con­sul­tant.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.